Clinical Trials · NCT05751226
A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Boehringer Ingelheim
- Enrollment
- 88
- Start date
- Apr 2023
- Locations
- 1 site, Germany
- Primary endpoint
- Percentage of treatment-emergent adverse events